This week's roundup of Houston innovators includes Enrique Gomez of Texas Medical Center Innovation, Katie Eick of Rockin' Pets Rollin' Vets, and Jim Gable of Chevron. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health care innovation to energy — recently making headlines in Houston innovation.

Enrique Gomez, entrepreneur in residence at Texas Medical Center Innovation

Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

When it comes to leading oncology innovation, Houston has a seat at the table, Enrique Gomez, entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, says on the Houston Innovators Podcast.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."Click here to read more and stream the episode.

Katie Eick, founder of Rollin' Vets

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

Houston-based Rockin' Pets, Rollin' Vets, a full-service mobile veterinary clinic based in Houston, has closed a $5 million equity raise with plans to expand across the Lone Star State. Founded by Dr. Katie Eick, who is the company's CEO, Rollin’ Vets Group flips the switch on pet health care by bringing vets to its patients' homes.

This fresh funding helps Eick take that first step toward expansion. According to a news release, Rockin’ Pets, Rollin’ Vets expects to have a presence in Dallas and Austin by March of next year.

“This equity raise allows us to not only hire additional talent, but also increase our mobile clinic fleet, while expanding into other cities at an expedited rate. There is a vast opportunity to serve animals and people that need non-traditional veterinary care in other Texas markets. We are ready to tap into these markets and bring convenient, state-of-the-art care straight to pet owners’ doorsteps,” says Eick in the release. Click here to read more.

Jim Gable, incoming vice president of innovation and president of Chevron Technology Ventures

Barbara Burger has led Chevron's innovation efforts for almost a decade and is passing the responsibilities to Jim Gable. Photo courtesy

Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, is retiring, and passing the role to Jim Gable.

Gable brings his 23 years of experience to the role. Based in Chevron's office on the West Coast, he will be relocating to Houston, per the release. He currently oversees the development and deployment of downstream-related technology for Chevron.

“CTV has a 22-year history of investing in startups across a wide cross section of energy innovation and a track record of collaboration to bring innovation to scale,” Bonner continues. “Jim’s experience at Chevron is deep and diverse. Combined with his technology commercialization experience with CTV early in his career, as well as in his current role, Jim is poised to lead CTV to even greater success.” Click here to read more.

Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

How Houston is emerging as a leader for oncology innovation, according to this expert

Houston innovators podcast episode 114

Houston is currently establishing itself as a hub for health care innovation — and Enrique Gomez should know. He's worked in the field of biopharmaceuticals across the continent.

As entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, he works with early stage startups and researchers. However, for decades he's worked in a much later stage of drug development, holding leadership positions at Takada in Latin America and Shire in Boston.

"Texas is very well recognized for cancer therapeutics," Gomez says on this week's episode of the Houston Innovators Podcast. "There's a lot of research going on. These researchers are looking at every angle — every possible strategy to tackle cancer."

At ACT, Gomez connects the startups or instigators with the resources they need to get their life-saving solutions to market. With cancer, there's not one thing that's going to work. There have to be options for treating cancer.

"Cancer is very heterogeneous. Not one strategy will be the single silver bullet to overcome the disease," Gomez says. "We are talking about personalized medicine. Every person is different and every cancer in every patient is different. It will require a number of approaches to overcome the health situation."

Thankfully, through TMC's ACT and the numerous research institutions working on the future of oncology, Houston's a great spot to move that needle.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."

He shares more on how COVID-19 has affected drug development and research — as well as what's next for his own career — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.